 |
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2023, vol. 29, issue1
Subject Area: Medicine
-
DOI: 10.5272/jimab.2023291.4784
Published online: 27 January 2023
Original article
J of IMAB. 2023 Jan-Mar;29(1):4784-4788
MODIFICATION OF [18F]FDG BY THE FORMATION OF A HYDRAZONE BOND
Gergana Simeonova1,2
, Boyan Todorov2,
1) Clinic Nuclear Medicine, UMHAT “St. Marina”, Medical University, Varna, Bulgaria.
2) Department of Analytical Chemistry, Faculty of Chemistry and Pharmacy, Sofia University, Bulgaria.
ABSTRACT:
Purpose: The [18F]-fluorodeoxyglucose ([18F]-FDG) is known to be one of the most used radio-pharmaceuticals for positron emission tomography. [18F]-FDG allows the assessment of glycolytic activity, which is more enhanced in tumor cells than in normal cells. It is also used in the assessment of heart and neurological diseases. The aim of our work is to follow the possibility of modifying [18F]-fluorodeoxyglucose and to develop an indirect radiofluorination procedure applicable under standard clinical conditions.
Material/Methods: In the clinic of nuclear medicine at the University Hospital Sta. Marina-Varna, for routine clinical purposes, [18F]-FDG is produced by the nucleophilic method of fluorination, using mannose triflate as a precursor. In addition to being used as a universal radiopharmaceutical, [18F]-FDG may be involved as a prosthetic group in biorthogonal reactions. [18F]-glycosylation by oxime or hydrazone formation is a chemoselective method for indirect radiofluorination of sensitive molecules. The process can improve the pharmacokinetics and stability of the labeled compounds in the blood.
Results: We developed a method for modifying fluorine-deoxyglucose by forming a hydrazone bond with bifunctional tetrazine {3-[4-(6-phenyl-[1,2,4,5]-tetrazine-3-yl)-phenoxy]-propyl}-hydrazine) (Tz). The progress of the process and the product obtained were monitored by radio TLC. The radiolabeled tetrazine product will be used for future biorthogonal click reactions with trans-cyclooctene under physiological conditions.
Keywords: Radionuclide 18F, PET-CT, [18F]-FDG, prosthetic group, hydrazone formation, click chemistry, tetrazine, bioorthogonal reaction,
- Download FULL TEXT /PDF 1150 KB/
Please cite this article as: Simeonova G, Todorov B. Modification of [18F]FDG by the formation of a hydrazone bond. J of IMAB. 2023 Jan-Mar;29(1):4784-4788. DOI: 10.5272/jimab.2022281.4784
Correspondence to: Gergana Simeonova, UMHAT “St. Marina”, Cl. in Nuclear Medicine, 1, Hristo Smirnenski Blvd., Varna, Bulgaria; E-mail: gerimm@abv.bg
REFERENCES:
1. Carberry P, Lieberman BP, Ploessl K, Choi SR, Haase DN, Kung HF. New F-18 prosthetic group via oxime coupling. Bioconjug Chem. 2011 Apr 20;22(4):642-53. [PubMed]
2. Kilbourn MR. Fluorine-18 labeling of radiopharmaceuticals. The National Academies Press, Washington, DC. 1990. [Internet]
3. Ermert J, Neumaier B. The Radiopharmaceutical Chemistry of Fluorine-18: Nucleophilic Fluorinations. In: Radiopharmaceutical Chemistry. Lewis J, Windhorst A, Zeglis B. (eds). Springer, Cham. 03 April 2019. [Crossref]
4. Chain Y, Illanes L. [Radiofarmacos en medicina nuclear- fundamentos y aplicaciуn clнnica.] [inSpanish] Editorial de la Universidad Nacional de la Plata. 2015. [Internet]
5. De Guevara DL. [Clinical utility of oncological and no oncological PET/CT.] [in Spanish] Rev Med Clin Condes. 2013 Jan;24(1):78-87. [Crossref]
6. Wuest F, Hultsch C, Berndt M, Bergmann R. Direct labelling of peptides with 2-[18F] fluoro-2-deoxy-d-glucose ([18F]FDG). Bioorg Med Chem Lett. 2009 Sep 15;19(18):5426-8. [PubMed]
7. Schirrmacher R, Wängler B, Bailey J, Bernard-Gauthier V, Schirrmacher E, Wängler C. Small Prosthetic Groups in 18F-Radiochemistry: Useful Auxiliaries for the Design of 18F-PET Tracers. SeminNucl Med. 2017 Sep; 47(5):474-492. [PubMed]
8. Maschauer S, Prante O. Sweetening pharmaceutical radiochemistry by (18)f-fluoroglycosylation: a short review. Biomed Res Int. 2014;2014:214748. [PubMed]
9.Larsen D, Kietrys AM, Clark SA, Park HS, Ekebergh A, Kool ET. Exceptionally rapid oxime and hydrazone formation promoted by catalytic amine buffers with low toxicity. Chem Sci. 2018 May 21;9(23):5252-5259. [PubMed]
10. Li XG, Haaparanta M, Solin O. Oxime formation for fluorine-18 labeling of peptides and proteins for positron emission tomography (PET) imaging: A review. J Fluor Chem. 2012 Nov;143:49–56. [Crossref]
11. Kölmel DK, Kool ET. Oximes and Hydrazones in Bioconjugation: Mechanism and Catalysis. Chem Rev. 2017 Aug 9;117(15):10358-10376. [PubMed]
12. Wester HJ, Schottelius M. Fluorine-18 Labeling of Peptides and Proteins. In: Schubiger PA, Lehmann L, Friebe M. (eds). PET Chemistry. Ernst Schering Research Foundation Workshop, vol 64. Springer, Berlin, Heidelberg. 2007. [Crossref]
13.Kettenbach K, Schieferstein H, Ross TL. 18F-labeling using click cycloadditions. Biomed Res Int. 2014; 2014: 361329. [PubMed]
14. Simeonova G, Todorov B, Lyubomirova V. Modification of 18F-fluorodesoxy-glucose ([18F]FDG) radiopharmaceutical by oxime conjugation. RAP Conf Proc. 2021; 6:11–15. [Crossref]
15. Blackman ML, Royzen M, Fox JM. Tetrazine ligation: fast bioconjugation based on inverse-electron-demand Diels-Alder reactivity. J Am Chem Soc. 2008 Oct 15;130(41):13518-9. [PubMed].
Received: 02 August 2022
Published online: 27 January 2023